Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study.

doi:10.1016/j.dld.2012.01.017

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver - 1 Jul 2012

Belli Luca S, Volpes Riccardo, Graziadei Ivo, Fagiuoli Stefano, Starkel Peter, Burra Patrizia, Alberti Alberto B, Gridelli Bruno, Vogel Wolfgang, Pasulo Luisa, De Martin Eleonora, Guido Maria, De Carlis Luciano, Lerut Jan, Cillo Umberto, Burroughs Andrew K, Pinzello Giovambattista

Abstract excerpt

BACKGROUNDS/AIMS: We evaluated the effect of antiviral therapy on fibrosis progression in patients with histological features of mild/moderate HCV disease recurrence defined by a Grading score≥4 and Staging score up to 3 (Ishak) at 1 year after liver transplantation. METHODS: Seventy-three consecutive patients with mild/moderate recurrence were randomized either to no treatment or to receive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chi-Square Distribution

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Liver Cirrhosis

Share to Liver Transplantation

Share to Polyethylene Glycols

Share to Recurrence

Share to Ribavirin

Source

Open in PubMed

Identifiers

PMID: 22424641
DOI: 10.1016/j.dld.2012.01.017

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study.PMID 22424641Read ↗

A model to predict severe HCV-related disease following liver transplantation.Semantic proximity Read ↗

Evolution of fibrosis during HCV recurrence after liver transplantation--influence of IL-28B SNP and response to peg-IFN and ribavirin treatment.Semantic proximity Read ↗

Outcome of living donor liver transplantation for Egyptian patients with hepatitis C (genotype 4)-related cirrhosis.Semantic proximity Read ↗

Histological and clinical outcome after liver transplantation for hepatitis C.Semantic proximity Read ↗

Evolution of the NS3 and NS5B regions of the hepatitis C virus during disease recurrence after liver transplantation.Semantic proximity Read ↗

Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome.Semantic proximity Read ↗

Optimizing outcome of recurrent hepatitis C virus genotype 4 after living donor liver transplantation: moving forward by looking back.Semantic proximity Read ↗

Section 13. Short-course pretransplant antiviral therapy is a feasible and effective strategy to prevent hepatitis C recurrence after liver transplantation in genotype 2 patients.Semantic proximity Read ↗

Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation.Semantic proximity Read ↗

Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?Semantic proximity Read ↗

Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation.Semantic proximity Read ↗

Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.